Compare CRSP & MTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | MTDR |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.4B |
| IPO Year | 2016 | 2012 |
| Metric | CRSP | MTDR |
|---|---|---|
| Price | $56.49 | $42.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 14 |
| Target Price | ★ $71.50 | $60.92 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 02-10-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 3.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.24 |
| Revenue | $38,337,000.00 | ★ $3,556,751,000.00 |
| Revenue This Year | N/A | $14.67 |
| Revenue Next Year | $718.51 | N/A |
| P/E Ratio | ★ N/A | $6.71 |
| Revenue Growth | N/A | ★ 14.75 |
| 52 Week Low | $30.04 | $35.19 |
| 52 Week High | $78.48 | $64.05 |
| Indicator | CRSP | MTDR |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 51.64 |
| Support Level | $53.37 | $41.59 |
| Resistance Level | $60.73 | $43.38 |
| Average True Range (ATR) | 2.33 | 1.40 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 47.39 | 62.28 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.